



12-16-05

JAP3 Rec'd PCT

14 DEC 2005

PCJ
#7

PATENT DOCKET 206,953

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: DE LUCA ET AL.

EXAMINER:

SERIAL NO.: 10/531,853

ART UNIT:

FILED: April 18, 2005

FOR: TAXANES COVALENTLY
BOUNDED TO HYALURONIC
ACID OR HYALURONIC
ACID DERIVATIVES

December 14, 2005

STATEMENT OF FILING BY EXPRESS MAIL 37 C.F.R. § 1.10

This correspondence is being deposited with the United States Postal Service on December 14, 2005 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ER 842 053 788 US addressed to the Honorable Commissioner for Patents, Washington, D.C. 20231.

INFORMATION DISCLOSURE STATEMENT

**Honorable Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Sir:

This Information Disclosure Statement (hereinafter sometimes referred to as "IDS") is submitted in accordance with 37 C.F.R. §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the

above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. §1.97, as it is filed:

(Check one of the boxes opposite A-D)

☐ A. within three months of the filing date of the above-identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in the above-identified international application.

☒ B. before the mailing date of a first office action on the merits.

☐ C. after the times set forth in (A) and (B) above, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, and the necessary statement pursuant to 37 C.F.R. §1.97(e) appears below (see box "i") or the necessary fee is enclosed (see box "ii" below).

(check one of the boxes opposite "i" or "ii" below)

☐ i. (check the applicable statement)

☐ I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ I, the undersigned, hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

☐ ii. A check for the fee set forth in 37 C.F.R. §1.17(p), presently believed to be \$ 240.00, is enclosed.

☐ D. after the times set forth in (A), (B), and (C) above, but before payment of the issue fee, since Applicant petitions for the consideration of this Information Disclosure Statement by a petition enclosed herewith pursuant to 37 C.F.R. §1.97(d)(2), a check for the petition fee set forth in 37 C.F.R. §1.17(i), presently believed to be \$ 130.00, is enclosed, and the necessary statement pursuant to 37 C.F.R. §1.97(e) appears below:

(check the applicable statement)

☐ I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ I, the undersigned, hereby state that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

2. In accordance with 37 C.F.R. §1.98(a)(1), this IDS includes a list on form PTO-1449 of all patents, publications, or other information submitted for consideration by the Office, incorporated into this IDS as an attachment hereto. Pursuant to 37 C.F.R. §1.98(b): (i) each U.S. patent listed is identified by patentee, patent number, and issue date; (ii) each foreign patent or published foreign patent application is identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application; and (iii) each publication is identified by author (if any), title, relevant pages of the publication, date, and place of publication. A legible copy of each document listed is attached and incorporated into this IDS, except that no copy of any U.S. patent application is included pursuant to 37 C.F.R. §1.98(a)(2)(iii) and except as explained below.

(check the boxes opposite A and/or B and fill in blanks, if appropriate)

☐ A. Document(s) _____ is (are) substantively cumulative to document(s) _____, and, in accordance with 37 C.F.R. §1.98(c), only a copy of each of the latter document(s) is (are) attached.

☐ B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon for an earlier filing date under 35 U.S.C. §120:

[insert serial numbers and filing dates of prior applications]

These documents are identified by attaching hereto copies of the forms PTO-892 and/or PTO-1449 from the files of the prior application(s) and Applicant requests that they be considered and made of record in this application in accordance with 37 C.F.R. §1.98(d). Pursuant to 37 C.F.R. §1.98(d), copies of these documents need not be provided with this IDS.

(check paragraphs 3 and/or 4, if applicable)

☐ 3. Document(s) _____ is (are) not in the English language. In accordance with 37 C.F.R. §§1.98(a)(3), 1.98(c), it is stated that:

(check the applicable statement(s))

☐ English translation(s) of the document(s) _____ (or of the pertinent portions thereof) is (are) enclosed and, thus no concise explanation of their relevance is required, (see M.P.E.P., §609, p. 600-92).

☐ English-language equivalent(s) of the document(s) _____ (or of the pertinent portions thereof) which is (are) in fact translation(s) of the document(s) is (are) enclosed.

☐ The attached English-language version of a search report or other action by a foreign patent office in a counterpart foreign application which cites document(s) _____ and which indicates the degree of relevance found by the foreign office is submitted to satisfy the requirement for a concise explanation of the relevance of the document(s), (see M.P.E.P., §609, p. 600-93).

☐ A concise explanation of the relevance of document(s) _____ is set forth as follows:

[insert concise explanation of relevance]

☐ A concise explanation of the relevance of document(s) _____ can be found on page(s) _____ of the specification.


☐ A concise explanation of the relevance of document(s) _____ can be found on the attached sheet.

☐ 4. Other information being provided for the Examiner's consideration follows:

5. In accordance with 37 C.F.R. §§1.97(g), 1.97(h), the filing of this IDS shall not be construed as a representation that a search has been made or as an admission that information cited in this IDS is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b). Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

6. Please charge any deficiency or other fees or credit any refund or overpayment to
Deposit Account No. 01-0035.

Respectfully submitted,

A handwritten signature in black ink, reading "Jay S. Cinnamon". The signature is written in a cursive style with a horizontal line underneath the name.

Jay S. Cinnamon
Attorney for Applicants
Registration No. 24,156

ABELMAN, FRAYNE & SCHWAB
666 Third Avenue, 10th Floor
New York, NY 10017-5612
(212) 949-9022
(212) 949-9190
Wd\notar\12 14 05 deluca ids

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket Control No.
206,953Serial No.
10/531,853LIST OF RELATED ART CITED BY APPLICANT
(Use several sheets if necessary)

Rec'd PCT/PTO 14 DEC 2005

Applicant DE LUCA ET AL.

Filing Date

April 18, 2005

Group

U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AA						

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation YES NO
AL					

OTHER RELATED ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AR		Denizot et al., "Rapid Colorimetric Assay for Cell Growth and Survival Modifications to the Tetrazolium Dye Procedure Giving Improved Sensitivity and Reliability", Journal of Immunological Methods, Vol. 89, pgs. 271-277 (1986).
AS		Andrea Herrera Gayol et al, "Effect of Hyaluronan on Xenotransplanted Breast Cancer", Experimental and Molecular Pathology, Vol. 72, pgs 179-185 (2002).
AT		Luo et al., "A Hyaluronic Acid-Taxol Antitumor Bioconjugate Targeted to Cancer Cells", Biomacromolecules, Vol. 1, pgs. 208-218 (2000).
AU		Li et al., "Complete Regression of Well-Established Tumors Using a Novel Water Soluble Poly (L-Glutamic Acid)-Paclitaxel Conjugate", Cancer Research, Vol. 58, pgs. 2404-2409, (1998).
AV		Mellado et al., "Preparation and Biological Activity of Taxol Acetates", Biochemical and Biophysical Research Communications, Vol. 124, NO. 2, pgs 329-336 (1984).
AW		Huizing et al., "Taxanes: A New Class of Antitumor Agents", Cancer Investigation, Vol. 13, pgs. 381-404 (1995).
AX		Manfredi et al., "Taxol Binds to Cellular Microtubules", The Journal of Cell Biology, Vol. 94, pgs 688-696, (1982).
AY		Weiss et al., "Hypersensitivity Reactions From Taxol", Journal of Clinical Oncology, Vol. 8, No. 7, pgs. 1263-1268 (1990).
AZ		Nuijen et al., "Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes", Investigational New Drugs, Volume 19, pgs 143-153, (2001).
AR		Robert W. Pfeifer et al., "Precipitation of Paclitaxel During Infusion by Pump", Am J. Hospital Pharmacology, Vol. 50, pg. 2518, (1993).

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.